10 Best Performing Healthcare Stocks So Far in 2025

5. Guardant Health, Inc. (NASDAQ:GH)

YTD Performance: 57.51%

Number of Hedge Fund Holders: 28

Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company specializing in treating cancer through vast data sets, proprietary blood-based tests, and advanced analytics. The company’s solutions include recurrence detection, early detection, and treatment selection.

Guardant Health, Inc. (NASDAQ:GH) has experienced significant stock gains year-to-date. It has strong operations and reported solid preliminary fiscal Q4 results. Its revenue was around $200 million, reflecting a 29% growth and surpassing analyst estimates of $188.9 million. Its full-year 2024 revenue reached approximately $737 million, up 31% and exceeding analyst estimates of $723.9 million.

The company is expanding its Medicare coverage for Guardant Reveal, its liquid biopsy test for monitoring disease recurrence in patients with colorectal cancer. Guardant Health, Inc. (NASDAQ:GH) has also Resolved FDA concerns about respiratory toxicity in non-rodent studies, clearing a hurdle for its Investigational New Drug (IND) application. In addition, the company has obtained Medicare coverage for its minimal residual disease (MRD) test and launched a blood test for colorectal cancer. It takes the fifth spot on our list.